Larimar Therapeutics' CTI-1601 offers hope for Friedreich's ataxia patients, with promising trial results. Check out why LRMR ...

Biohaven said its experimental treatment for a rare neurological condition showed "a robust and clinically meaningful" ...

The US biotech’s neurological drug candidate showed a reduction in disease progression of at least 50% and the company will ...

Larimar Therapeutics (NASDAQ:LRMR) was started at outperform by Wedbush based on the company’s drug candidate nonlabofusp for ...

In 2023, the U.S. Food and Drug Administration approved the first medication to treat people with Friedreich’s ataxia who are age 16 or older. Given that Friedreich’s ataxia is a genetic ...

With fresh, positive data in hand, Biohaven now believes its medicine could be the first to receive FDA approval for spinocerebellar ataxia.

has granted Orphan Drug Designation to Papillon’s PPL-001, an experimental treatment for Friedreich's ataxia. “We are pleased that the FDA has granted Orphan Drug Designation to our program ...

Biohaven Ltd. shares rose sharply after its experimental drug slowed the progress of a rare nerve disease in a study, which ...

Biohaven Ltd. reported positive results from a pivotal study using troriluzole for the treatment of patients with ...

is pleased to announce today that Health Canada has accepted for priority review its New Drug Submission (NDS) for omaveloxolone, an innovative therapy for Friedreich's ataxia for the treatment of ...

In order to improve the quality of life of patients with the Ataxia disease, the biotechnological and pharmaceutical industry ...